CaroSpir® (spironolactone) – New drug approval
August 7, 2017 – CMP Pharma announced the FDA approval of CaroSpir (spironolactone) oral suspension, indicated for the treatment of New York Heart Association Class III - IV heart failure and reduced ejection fraction to increase survival, manage edema, and to reduce the need for hospitalization for heart failure (CaroSpir is usually administered in conjunction with other heart failure therapies); use as an add-on therapy for the treatment of hypertension, to lower blood pressure in adult patients inadequately controlled on other agents; and the management of edema in adult cirrhotic patients when edema is not responsive to fluid and sodium restriction.
Top